Biotech Values

[vinmantoo]

McBio,

I didn't get a chance to listen to the presentation, but $50 million in year 7 seems low in the current indication of Relistor in AMI. SLXP has only been in charge of distribution of Relistor for about 6 months, and last quarter Relistor sales were $10 million, up from less than half that in the previous quarter so I was assuming $50 million in sales could be reached this year, especially since SLXP is looking for a European distributor.

Clearly approval in the chronic pain indication will be a big sales driver, as will approval of the oral formulation. How long is the presentation?